Today, I review, link to, and excerpt from a press release from American Academy Of Neurology, Revolutionary Migraine Drug Delivers Relief From Day One, that was posted on SciTechDaily.
All that follows is from the above resource.
A groundbreaking study finds that Atogepant, the new migraine prevention drug, offers immediate relief, reducing migraine occurrences right from the first day of use, significantly enhancing life quality for patients.
A recently approved migraine prevention drug, atogepant, may start working immediately, according to a study published today (December 23, 2024)* in the online edition of Neurology, the journal of the American Academy of Neurology. Atogepant is an oral calcitonin gene-related peptide (CGRP) receptor antagonist designed to reduce migraine frequency.
*Early Improvements With Atogepant for the Preventive Treatment of Migraine Results From 3 Randomized Phase 3 Trials [Full-Text HTML]. Research Article, December 23, 2024. January 28, 2025 issue 104 (2) https://doi.org/10.1212/WNL.0000000000210212
